Table 1.

Demographics of FcγRIIIa-genotyped cohort

Demographics of cetuximab-treated, FcγRIIIa-genotyped cohort
RegimenNo. of patientsTumor siteMean age, yMalesFemales
UPCI 05-003a36OC352.9324
OP23
L4
HP3
Other1
Unknown primary2
UPCI 05-005b24OC058.2204
OP9
L5
HP4
Other4
Unknown primary2
Cetuximab11OC465.4101
OP1
L1
HP0
Other5
Unknown primary0
Cetuximab + radiotherapy36OC1062.5306
OP12
L3
HP2
Other8
Unknown primary1

Abbreviations: OC, oral cavity; OP, oropharynx; L, larynx; HP, hypopharynx.

  • aCetuximab 250 mg/m2 days weekly (after an initial dose of 400 mg/m2), docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, repeated every 21 days × 3 cycles, then radiotherapy to 70 Gy (2 Gy/d) with concurrent cetuximab 250 mg/m2 weekly + cisplatin 30 mg/m2, then maintenance cetuximab for 6 months. Blood was drawn during single-agent cetuximab maintenance.

  • bCetuximab 250 mg/m2 (after an initial dose of 400 mg/m2) weekly + pemetrexed on days 1, 22, and 43 with concurrent radiotherapy (2 Gy/d).